2JIX

Crystal structure of ABT-007 FAB fragment with the soluble domain of EPO receptor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.2 Å
  • R-Value Free: 0.323 
  • R-Value Work: 0.257 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

A Potent Erythropoietin-Mimicking Human Antibody Interacts Through a Novel Binding Site.

Liu, Z.Stoll, V.S.Devries, P.Jakob, C.G.Xie, N.Simmer, R.L.Lacy, S.E.Egan, D.A.Harlan, J.E.Lesniewski, R.R.Reilly, E.B.

(2007) Blood 110: 2408

  • DOI: 10.1182/blood-2007-04-083998

  • PubMed Abstract: 
  • Recombinant human erythropoietin (rHu-EPO) is used to treat anemia by activating the erythropoietin receptor (EPOR) in erythroid progenitor cells, leading to proliferation and differentiation into mature red blood cells. To allow less frequent dosing ...

    Recombinant human erythropoietin (rHu-EPO) is used to treat anemia by activating the erythropoietin receptor (EPOR) in erythroid progenitor cells, leading to proliferation and differentiation into mature red blood cells. To allow less frequent dosing, a hyperglycosylated version of EPO has been developed with a longer half-life. In principle, an agonistic antibody targeting EPOR would offer an even longer half-life, support robust monthly dosing, and, unlike EPO products, reduce the risk of pure red cell aplasia. The efficiency of signaling and corresponding potency of previously reported antibody mimics are generally suboptimal compared with EPO and not suitable for clinical use. Here we describe a potent, fully human, agonistic antibody (ABT007) targeting EPOR that supports potent, more sustained, and less pulsatile elevation of hematocrit in a human EPOR-expressing transgenic mouse model compared with standard doses of rHu-EPO while requiring less frequent dosing. Resolution of the crystal structure of the EPOR extracellular domain (ECD) complexed to the ABT007 Fab fragment, determined at 0.32 nm, identifies a binding site that is consistent with a novel mechanism of receptor activation based on a unique antibody-imposed conformational change. These results demonstrate that a symmetric molecule can serve as a potent activator of the EPOR.


    Organizational Affiliation

    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6199, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
ABT-007 FAB FRAGMENT
A, G, L
214Homo sapiensMutation(s): 0 
Find proteins for Q7Z3Y4 (Homo sapiens)
Go to UniProtKB:  Q7Z3Y4
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
ERYTHROPOIETIN RECEPTOR
B, C, E
225Homo sapiensMutation(s): 0 
Gene Names: EPOR
Find proteins for P19235 (Homo sapiens)
Go to Gene View: EPOR
Go to UniProtKB:  P19235
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
ABT-007 FAB FRAGMENT
D, F, H
217Homo sapiensMutation(s): 0 
Gene Names: IGH@
Find proteins for Q6GMX6 (Homo sapiens)
Go to UniProtKB:  Q6GMX6
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.2 Å
  • R-Value Free: 0.323 
  • R-Value Work: 0.257 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 117.954α = 90.00
b = 156.171β = 90.00
c = 164.205γ = 90.00
Software Package:
Software NamePurpose
REFMACrefinement
PHASERphasing
MOLREPphasing
HKL-2000data reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2007-07-10
    Type: Initial release
  • Version 1.1: 2013-10-30
    Type: Source and taxonomy, Version format compliance